Evidence map›Paper›PMID 11145206›Full record

ReviewBrain pathology (Zurich, Switzerland)2001

Viral induced demyelination.

S A Stohlman, D R Hinton

Open access · bronzeAbstract readReview
In one paragraph

Review in Brain pathology (Zurich, Switzerland), 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 166 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Open biology · 2024
    Article
  5. The immune system in neurological diseases: What innate-like T cells have to say.The Journal of allergy and clinical immunology · 2024
    Review
  6. Review
  7. Visual evoked potential abnormalities in patients with COVID-19.Revista da Associacao Medica Brasileira (1992) · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

S A StohlmanDepartment of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 90033, USA. stohlman@hsc.usc.edu
D R Hinton
Southern California University for Professional Studies · USUniversity of Southern California · US

Funding

VIRUS ENTRY AS A DETERMINANT OF MOUSE HEPATITIS VIRUS NEUROTROPISMP01NS018146 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI STOHLMAN, STEPHEN A. · 1985 to 2007
$10.4M
NINDS NIH HHS NS18146
6 · The paper itself

Abstract

Viral induced demyelination, in both humans and rodent models, has provided unique insights into the cell biology of oligodendroglia, their complex cell-cell interactions and mechanisms of myelin destruction. They illustrate mechanisms of viral persistence, including latent infections in which no infectious virus is readily evident, virus reactivation and viral-induced tissue damage. These studies have also provided excellent paradigms to study the interactions between the immune system and the central nervous system (CNS). Although of interest in their own right, an understanding of the diverse mechanisms used by viruses to induce demyelination may shed light into the etiology and pathogenesis of the common demyelinating disorder multiple sclerosis (MS). This notion is supported by the persistent view that a viral infection acquired during adolescence might initiate MS after a long period of quiescence. Demyelination in both humans and rodents can be initiated by infection with a diverse group of enveloped and non-enveloped RNA and DNA viruses (Table 1). The mechanisms that ultimately result in the loss of CNS myelin appear to be equally diverse as the etiological agents capable of causing diseases which result in demyelination. Although demyelination can be a secondary result of axonal loss, in many examples of viral induced demyelination, myelin loss is primary and associated with axonal sparing. This suggests that demyelination induced by viral infections can result from: 1) a direct viral infection of oligodendroglia resulting in cell death with degeneration of myelin and its subsequent removal; 2) a persistent viral infection, in the presence or absence of infectious virus, resulting in the loss of normal cellular homeostasis and subsequent oligodendroglial death; 3) a vigorous virus-specific inflammatory response wherein the virus replicates in a cell type other than oligodendroglia, but cytokines and other immune mediators directly damage the oligodendroglia or the myelin sheath; or 4) infection initiates activation of an immune response specific for either oligodendroglia or myelin components. Virus-induced inflammation may be associated with the processing of myelin or oligodendroglial components and their presentation to the host's own T cell compartment. Alternatively, antigenic epitopes derived from the viral proteins may exhibit sufficient homology to host components that the immune response to the virus activates autoreactive T cells, i.e. molecular mimicry. Although it is not clear that each of these potential mechanisms participates in the pathogenesis of human demyelinating disease, analysis of the diverse demyelinating viral infections of both humans and rodents provides examples of many of these potential mechanisms.

Indexed as

AnimalsCell DeathCentral Nervous System InfectionsDemyelinating DiseasesHumansLeukoencephalopathy, Progressive MultifocalMiceModels, AnimalMurine hepatitis virusOligodendrogliaSubacute Sclerosing PanencephalitisTheilovirusVirus Diseases

Identifiers

PMID11145206
PMCPMC7161848
OpenAlexW2062357047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.